United Kingdom

Conatus Pharmaceuticals Inc (CNAT.OQ)

CNAT.OQ on NASDAQ Stock Exchange Global Market

10 Dec 2018
Change (% chg)

$-0.21 (-12.28%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Get access to over 18 million research reports from over 1,700 sources.

For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.

Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.

Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:

  • ownership
  • filings
  • deals
  • private equity
  • third-party document and information retrieval
  • estimates
  • fundamentals
  • economics
  • events
  • news
  • and much, much more…

Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.

Name Age Since Current Position

David Hale

67 2012 Independent Chairman of the Board

Steven Mento

66 2017 President, Chief Executive Officer, Director

Keith Marshall

2017 Chief Financial Officer, Principal Financial Officer, Chief Operating Officer, Executive Vice President

Alfred Spada

57 2015 Executive Vice President - Research & Development, Chief Scientific Officer

David Hagerty

60 2014 Executive Vice President, Clinical Development